Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

Vaccine

Volumn 17, Issue SUPPL. 2, 1999, Pages

  Levine, Myron M ^a,b   Ferreccio, Catterine ^c   Abrego, Paulina ^b   Martin, Oriana San ^b   Ortiz, Edith ^d   Cryz, Stanley ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Centro para Vacunas en Desarrollo Chile   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d Ministerio de Salud de Chile   (Chile)

^e Berna Biotech AG   (Switzerland)

Author keywords

Immunization; Typhoid fever; Vaccines

Indexed keywords

LIVE VACCINE; TYPHOID VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; CHILD; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; ENTERIC COATED TABLET; HUMAN; PRIORITY JOURNAL; SALMONELLA TYPHI; TYPHOID FEVER; VACCINATION;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHILE; DOUBLE-BLIND METHOD; HUMANS; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TREATMENT OUTCOME; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 0033215117     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00231-5     Document Type: Conference Paper

References (32)

1. Germanier R., Furer E. Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141:1975;553-558.
2. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1:1987;1049-1052.
3. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine. 8:1990;81-84.
4. Ferreccio C., Levine M.M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159:1989;766-769.
5. Levine M.M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
6. Simanjuntak C, Paleologo F, Punjabi N, Darmowitogo R, Soeprawato, Totosudirjo H, Haryanto P, Suprijanto E, Witham N, Hoffman SL, Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-59.
7. Levine M.M., Taylor D.N., Ferreccio C. Typhoid vaccines come of age. Pediatr. Infect. Dis. J. 8:1989;374-381.
8. Ivanoff B., Levine M.M. Typhoid fever: continuing challenges from a resilient bacterial foe. Bull. Inst. Pasteur. 95:1997;129-142.
9. Ivanoff B., Levine M.M., Lambert P.H. Vaccination against typhoid fever: present status. Bull. Wld. Hlth. Org. 72:1994;957-971.
10. Bhutta Z.A. Impact of age and drug resistance on mortality in typhoid fever. Arch. Dis. Child. 75:1996;214-217.
11. Bhutta Z.A. Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Ann. Trop. Paediatr. 16:1996;299-306.
12. Bhutta Z.A., Naqvi S.H., Razzaq R.A., Farooqui B.J. Multidrug-resistant typhoid in children: presentation and clinical features. Rev. Infect. Dis. 13:1991;832-836.
13. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr. Infect. Dis. 13:1994;124-140.
14. Hoa N.T., Diep T.S., Wain J., Parry C.M., Hien T.T., Smith M.D., Walsh A.L., White N.J. Community-acquired septicaemia in southern Vietnam: the importance of multidrug-resistant Salmonella typhi. Trans. R. Soc. Trop. Med. Hyg. 92:1998;503-508.
15. Nguyen T.C., Solomon T., Mai X.T., Nguyen T.L., Nguyen T.T., Wain J., To S.D., Smith M.D., Day N.P., Le T.P., Parry C., White N.J. Short courses of ofloxacin for the treatment of enteric fever. Trans. R. Soc. Trop. Med. Hyg. 91:1997;347-349.
16. Parry C., Wain J., Chinh N.T., Vinh H., Farrar J.J. Quinolone-resistant Salmonella typhi in Vietnam. Lancet. 351:1998;1289.
17. Tran T.H., Bethell D.B., Nguyen T.T., Wain J., To S.D., Le T.P., Bui M.C., Nguyen M.D., Pham T.T., Walsh A.L. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin. Infect. Dis. 20:1995;917-923.
18. Wain J., Hoa N.T., Chinh N.T., Vinh H., Everett M.J., Diep T.S., Day N.P., Solomon T., White N.J., Piddock L.J., Parry C.M. Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:1997;1404-1410.
19. Mikhail I.A., Haberberger R.L., Farid Z., Girgis N.I., Woody J.N. Antibiotic-multiresistant Salmonella typhi in Egypt. Trans. R. Soc. Trop. Med. Hyg. 83:1989;120.
20. World Health Organization. Report of the Meeting of the Scientific Advisory Group of Experts (SAGE), June 1998. WHO/GPV/98.06:42.
21. Batson A. Win-win interactions between the public and private sectors. Nat. Med. 4:1998;487-491.
22. Ferreccio C. Typhoid: Policy quandaries about use of Ty21a in Chile. Sack D.A., Freij L. Prospects for public health benefits in developing countries from new vaccines against enteric infections. 1990;67-81 Gotab, Stockholm.
23. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Sears S, Morris JG, Cisneros L, Germanier R, Chilean Typhoid Commission. Interventions to control endemic typhoid fever: Field studies in Santiago, Chile. PAHO Copublication Series No. 1, Washington, DC 1986, pp. 37-53.
24. Mahle W.T., Levine M.M. Salmonella typhi infection in children younger than five years of age. Pediatr. Infect. Dis. J. 12:1993;627-631.
25. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., Germanier R. Progress in vaccines to prevent typhoid fever. Rev. Infect. Dis. 11:1989;S552-S567.
26. Levine M.M. Typhoid fever vaccines. Plotkin S.A., Mortimer E. Jr. Vaccines. 2nd ed :1994;597-633 Saunders WB, Philadelphia.
27. Ashcroft M.T., Morrison-Ritchie J., Nicholson C.C. Controlled field trial in British Guiyana schoolchildren of heat-killed phenolized and acetone-killed lyophilized typhoid vaccines. Am. J. Hyg. 79:1964;196-206.
28. Ashcroft M.T., Nicholson C.C., Balwant S., Ritchie J.M., Sorvan E., William F. A seven-year field trial of two typhoid vaccines in Guiana. Lancet. 2:1967;1056-1060.
29. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 14:1996;435-438.
30. Klugman K., Gilbertson I.T., Kornhoff H.J., Robbins J.B., Schneerson R., Schulz D., Cadoz M., Armand J. Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet. 2:1987;1165-1169.
31. Tacket C.O., Levine M.M., Robbins J.B. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine. 6:1988;307-308.
32. Levine M.M., Black R.E., Ferreccio C., Clements M.L., Lanata C., Rooney J., Germanier R. The efficacy of attenuated Salmonella typhi oral vaccine strain Ty21a evaluated in controlled field trials. Holmgren J., Lindberg A., Molly R. Development of vaccines and drugs against diarrhoea. 1986;90-101 Studentlitteratur Lund, Sweden.